Catalent Company Overview
About Catalent
Catalent (NYSE:CTLT) operates in the pharmaceutical industry, specializing in delivery technologies, development solutions, and manufacturing for drugs, biologics, gene therapies, and consumer health products. The company is known for its innovative approaches to solving some of the most pressing challenges in drug development and delivery, including enhancing bioavailability, optimizing drug delivery, and increasing the speed to market for new therapies. Catalent's projects range from early-stage development to full-scale production, and its objectives are focused on leveraging its expertise and technology platforms to accelerate the pace of innovation in healthcare, ensuring medicines are made more accessible and affordable to patients worldwide. Its operations span a global network, aiming to deliver high-quality solutions that improve patient outcomes and drive the future of medicine.
Snapshot
Operations
Products and/or services of Catalent
- Biologics development and manufacturing services, offering full-scale production for proteins, monoclonal antibodies, and cell therapies.
- Oral solid dose development, including advanced delivery technologies for tablets and capsules.
- Gene therapy services, providing viral vector development and manufacturing for gene-modified cell therapies.
- Softgel and oral dose formulation, leveraging unique technology for better bioavailability and patient compliance.
- Clinical supply services, offering global solutions for trial management, packaging, and distribution.
- Respiratory and ophthalmic formulation services, focusing on inhaled therapies and treatments for eye diseases.
Catalent executive team
- Mr. John J. Greisch M.B.A.Executive Chairman of the Board
- Mr. Alessandro MaselliPresident, CEO & Director
- Mr. Matti M. MasanovichSenior VP & CFO
- Ms. Lisa EvoliSenior VP & Chief Human Resources Officer
- Mr. Ricky HopsonPresident, Division Head for BioProduct Delivery & Chief of Staff
- Mr. David McErlaneGroup President of Biologics Segment
- Mr. Michael J. Hatzfeld Jr.VP & Chief Accounting Officer
- Mr. Charles LickfoldSenior VP & Chief Information Officer
- Mr. Paul SurdezVice President of Investor Relations
- Mr. Joseph A. Ferraro J.D.Senior VP, General Counsel, Chief Compliance Officer & Corporate Secretary